Nerai pioneers novel highly personalized CRISPR proteins to deliver lifelong cures for diseases beyond the reach of current genome editing. By fusing AI with programmable biology, its editors redefine what is achievable in the safety, efficiency, and targetability of genetic medicine. With lead programs targeting multi-billion markets in rare liver and eye disease and strong biopharma traction for its platform technology, Nerai is poised to become a key European-based player in vivo genome editing.
30.06.2025
Venture Leaders Biotech 2025 connects Swiss science with the US biotech market (venturelab.swiss)
02.06.2025
Nerai Bioscience: The Venture Leader Biotech redefining genetic medicine (venturelab.swiss)
22.05.2025
18 startups selected for >>venture>> final pitches (startupticker.ch)
06.05.2025
Venture Leaders Biotech 2025 kick off at Swiss Biotech Day ahead of Boston roadshow (venturelab.swiss)
26.03.2025
Venture Leaders Biotech 2025 cohort revealed (startupticker.ch)
01.06.2025
Top3 finalist of >>venture>>
19.02.2025
Nerai is incorporated - long live Nerai!
01.01.2025
Innosuisse Innovation Project
01.11.2024
Venture Kick Stage 3
01.09.2024
GRS Innobooster
No Jobs
No videos and documents
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Website:
www.nerai.bio
Headquarter:
Zürich
Foundation Date:
February 2025
Technology:
Sectors: